.webp){kind=small}
Science & Technology — Intellectual Property
Patent Portfolio & Intellectual Property
Annovis Bio holds a growing portfolio of issued and pending patents protecting buntanetap's composition of matter, mechanism of action, clinical applications, and combination therapies across neurodegenerative and acute neurological indications. Our intellectual property strategy is designed to provide long-term market exclusivity and support the full commercial lifecycle of buntanetap.
10
+
Issued & pending patents worldwide
3
Issued & pending patents worldwide
2040
s
Issued & pending patents worldwide
6
+
Issued & pending patents worldwide
Portfolio overview
Annovis's intellectual property estate has been systematically built around buntanetap — from its foundational composition of matter through clinical application and manufacturing. The portfolio spans four broad categories:
Coverage areas
Composition of matter (original & crystal form)
Mechanism of action — IRP/IRE pathway modulation
Method of use — neurodegenerative disease treatment
Method of use — acute neurological injury
Combination therapies (GLP-1, PDE5 inhibitors)
Novel manufacturing process (crystalline form)
Indications protected
Alzheimer's disease (AD)
Parkinson's disease (PD)
Frontotemporal dementia (FTD)
ALS & Huntington's disease
Traumatic brain injury & stroke
Neurological injury from brain infections
Key issued & filed patents
The table below summarizes Annovis's principal patents and applications. Additional patents pending in the US and international jurisdictions are not listed.
Patent / App. No.
Title / Scope
Coverage
Expiry
Geography
Status
US 10,383,851
Method of treating Parkinson's disease
Method of use — buntanetap in PD; axonal transport restoration
2037
🇺🇸 US
Granted
EP 2683242
Method of treating Alzheimer's disease
Method of use — buntanetap in AD; amyloid precursor protein translation inhibition
2037
🇪🇺 EU
Granted
US 17/XXXXXX
Crystalline form of buntanetap (ANVS402)
Composition of matter — new solid-state form; improved stability & purity; all chronic and acute neurodegenerative indications
2043
🇺🇸 US (intl. pending)
Pending
US Prov. 2024
Manufacturing process — crystalline buntanetap
Synthesis route from starting materials to GMP-grade product; genotoxic-reagent-free; scalable to ton quantities
2044
🇺🇸 US
Filed
US Prov. 2024-A
Buntanetap + GLP-1 agonist combination
Combination therapy with dulaglutide (Trulicity) for cognitive enhancement in AD & PD
2044
🇺🇸 US
Filed
US Prov. 2024-B
Buntanetap + PDE5 inhibitor combination
Combination therapy with sildenafil (Viagra) for cognitive enhancement in neurodegenerative disease
2044
🇺🇸 US
Filed
US Prov. 2024-C
Triple combination therapy
Buntanetap + dulaglutide + sildenafil; synergistic cognitive benefit demonstrated in AD mouse models
2044
🇺🇸 US
Filed
US 2025-NI
Treatment of neurological injury from brain infections
Method of use — buntanetap for acute neurological injury caused by viral, bacterial, and parasitic CNS infections
2045
🇺🇸 US
Granted
Patent numbers marked as provisional or with placeholder identifiers reflect filings pending full examination and publication. Expiry years are estimates based on filing date + 20-year statutory term and do not account for potential Patent Term Extension (PTE). This table is provided for informational purposes only and does not constitute a comprehensive statement of Annovis Bio's intellectual property position. Investors should refer to Annovis's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC for a complete discussion of intellectual property.
IP strategy
Annovis has developed a layered IP strategy designed to protect buntanetap at every stage of its commercial lifecycle — from the underlying molecule and its improved forms to its methods of use across an expanding set of neurological indications and its role in synergistic combination regimens. The recent transition to the crystalline form of buntanetap resets the composition of matter clock, providing protection expected to extend into the mid-2040s.
Annovis continues to actively file new applications as clinical data and preclinical findings generate patentable inventions. The combination therapy filings represent a forward-looking layer of IP designed to protect buntanetap's role in next-generation multi-mechanism treatment regimens, consistent with the evolving scientific consensus on the multi-protein nature of neurodegeneration.
Licensing & investor inquiries
For licensing inquiries or investor due diligence requests related to Annovis's intellectual property portfolio, please contact our corporate communications team.
.svg)
.svg)
.svg)
.svg)
